-
Synta Announces Publication of Results Showing Ganetespib Exhibits Potent Activity in Models of Cancer with Activated JAK/STAT Signaling
Thursday, May 26, 2011 - 8:15am | 68Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the publication in the on-line edition of the journal PLoS ONE of results demonstrating that ganetespib, a potent second generation inhibitor of heat shock protein 90, exhibits potent in vitro and in vivo activity in a range of solid and...
-
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Thursday, May 26, 2011 - 8:13am | 140Arena Pharmaceuticals (NASDAQ: ARNA) today presented meta-analyses of the three trials in the lorcaserin Phase 3 clinical trial program at ECO 2011, the 18th European Congress on Obesity. The analyses show that lorcaserin caused statistically significant weight loss compared to placebo at one year...
-
BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology
Thursday, May 26, 2011 - 7:00am | 164BioCryst Pharmaceuticals (NASDAQ: BCRX) today presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, U.K...
-
Pharmasset Announces All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
Thursday, May 26, 2011 - 6:58am | 76Pharmasset, Inc. (Nasdaq: VRUS) announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's (NYSE: BMY) NS5A replication complex inhibitor, for the treatment of chronic...
-
Aastrom Announces Collaboration With CPC Clinical Research for the Phase 3 REVIVE Study in Critical Limb Ischemia
Wednesday, May 25, 2011 - 5:00pm | 183Aastrom Biosciences (Nasdaq: ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced a collaborative agreement with CPC Clinical Research, a non-profit, academic research organization led by...
-
Dynavax Completes Phase 3 Study of HEPLISAV
Wednesday, May 25, 2011 - 4:31pm | 61Dynavax Technologies Corporation (NASDAQ: DVAX) today reported completing the 12-month follow-up on all of the 2,449 subjects enrolled in its large-scale Phase 3 study of HEPLISAV evaluating immunogenicity in comparison to Engerix, lot-to-lot consistency and safety. With the study's completion,...
-
Rigel Announces Proposed Public Offering of Common Stock
Wednesday, May 25, 2011 - 4:02pm | 106Rigel Pharmaceuticals (Nasdaq: RIGL), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Rigel. The offering is subject to market and other conditions, and there can be no assurance as...
-
InterMune to Provide Overview of Corporate Strategy; Sees R&D Expenses of $85-$95 Million
Wednesday, May 25, 2011 - 4:01pm | 118InterMune (NASDAQ: ITMN) will outline the company's corporate strategy and vision for 2015, including an update on its ongoing plans to commercialize Esbriet in Europe, as well as details on ASCEND, a new Phase 3 pirfenidone study, during a meeting with analysts in New York tomorrow, May 26....
-
Puts Purchased on Acorda Therapeutics
Wednesday, May 25, 2011 - 3:23pm | 128Shares of Acorda Therapeutics (NASDAQ: ACOR) are higher on the session by 3.76%, currently trading at $32.84. The stock has been moving largely higher over the past three months and is currently trading above the 200-day moving average. Options traders are buying puts on the name today. A short...
-
Amarin Continues To Rise; Profiled On Fast Money
Wednesday, May 25, 2011 - 1:23pm | 181Amarin Corp. (NASDAQ: AMRN) released positive trial data on its leading drug candidate AMR101 on April 18th. The Phase III trial, known as ANCHOR, was geared towards the treatment of cardiovascular disease and met all of its primary and secondary endpoints. Another Phase III trial, MARINE,...
-
Options Brief: Seattle Genetics, Inc.
Wednesday, May 25, 2011 - 11:11am | 78Shares of Seattle Genetics, Inc. (NASDAQ: SGEN) are higher on the session by 1.34%, trading at $18.91. Overall put volume is now running at 3.04x the daily average, with 52% of all puts traded being purchases on the offer. 2,548 contracts have traded on the session so far. Seattle Genetics, Inc...
-
BioCryst Pharmaceuticals Announces Appointment of Thomas Staab as Its Next CFO
Wednesday, May 25, 2011 - 9:25am | 54BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the appointment of Mr. Thomas R. Staab, II as BioCryst's new Chief Financial Officer, effective July 1, 2011, and that Mr. Stuart R. Grant, BioCryst's current CFO, has agreed to extend his employment with the Company an additional month...
-
Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease
Wednesday, May 25, 2011 - 8:03am | 72Sinovac Biotech Ltd. (NASDAQ: SVA) announced today the unblinded results of its Phase I clinical trial for its proprietary inactivated vaccine against human enterovirus 71, which causes Hand, Foot, and Mouth Disease. The safety observation results for the EV71 vaccine for all three age groups...
-
Morgan Stanley Reports Vertex Pharmaceuticals
Wednesday, May 25, 2011 - 7:49am | 199Morgan Stanley commented on Vertex Pharmaceuticals (NASDAQ: VRTX) in a report released yesterday. In the report, Morgan Stanley was negative in its assessment of the company. Morgan Stanley writes, "We believe the Street is overestimating the sales growth trajectory of Vertex's novel hepatitis C (...
-
Brean Murray Raises PT on Aria Pharmaceuticals To $11
Wednesday, May 25, 2011 - 7:28am | 29Brean Murray Carret & Company has raised the price target on Ariad Pharmaceuticals (NASDAQ: ARIA) from $9 to $11 and maintains its Buy rating.